Sector News

AstraZeneca to carve out antibiotic R&D into separate firm

February 27, 2015
Life sciences
(Reuters) – Drugmaker AstraZeneca has decided to carve out its early-stage antibiotic research by creating a stand-alone subsidiary company, as it sharpens its focus on other therapy areas.
 
Chief Executive Pascal Soriot said last year he was looking to partner or sell its anti-infective business, which is no longer viewed as a core area for the British drugmaker.
 
AstraZeneca said in an emailed statement it would invest $40 million in the new antibiotic company, which will include early-stage products such as a drug in Phase II for gonorrhoea. The move will impact approximately 95 employees based in Waltham, Massachusetts.
 
The new structure has no impact on anti-infective products already on the market, including Merrem, Zinforo, Fluenz/Flumist and Synagis. It also does not affect Avycaz, a new antibiotic approved this week from Actavis, which was co-developed with AstraZeneca.
 
Antibiotics have fallen out of favour in the past decade among many Big Pharma companies, because of their typically low margins. The industry has focused instead on more profitable areas, like cancer.
 
More recently some companies have started coming back to the space, given the demand for novel medicines that can fight drug-resistant superbugs, with Merck & Co agreeing to buy Cubist for $8.4 billion in December.
 
But AstraZeneca prefers to deploy its resources on its three priority areas of oncology; cardiovascular and metabolic diseases; and respiratory and inflammation.
 
The decision to carve-out early-stage antibiotics fits with Soriot’s aim of doing more so-called “externalisation”, involving the sale of non-core drugs, both to increase the company’s focus and generate additional income to see it through a tough period of patient expiries on older drugs.
 
Last year it struck a partnership deal worth up to $500 million for Alzheimer’s treatment with Eli Lilly, which could be a model for further transactions.
 
(Reporting by Ben Hirschler, editing by William Hardy)

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).